

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Vivo Capital VIII, LLC</u>  (Last) (First) (Middle) <u>C/O VIVO CAPITAL LLC</u> <u>192 LYTTON AVENUE</u>  (Street) <u>PALO ALTO CA 94301</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Crinetics Pharmaceuticals, Inc. [ CRNX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>02/07/2020</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/07/2020		S		1,134	D	\$22 <sup>(6)</sup>	2,723,843	I	See footnotes <sup>(1)(4)</sup>
Common Stock	02/07/2020		S		157	D	\$22 <sup>(6)</sup>	376,128	I	See footnotes <sup>(2)(4)</sup>
Common Stock	02/07/2020		S		4,614	D	\$22 <sup>(6)</sup>	174,202	I	See footnotes <sup>(3)(5)</sup>
Common Stock	02/10/2020		S		1,451	D	\$21.4 <sup>(7)</sup>	2,722,392	I	See footnotes <sup>(1)(4)</sup>
Common Stock	02/10/2020		S		200	D	\$21.4 <sup>(7)</sup>	375,928	I	See footnotes <sup>(2)(4)</sup>
Common Stock	02/10/2020		S		5,904	D	\$21.4 <sup>(7)</sup>	168,298	I	See footnotes <sup>(3)(5)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person \*

[Vivo Capital VIII, LLC](#)

(Last) (First) (Middle)  
C/O VIVO CAPITAL LLC  
192 LYTTON AVENUE

(Street)  
PALO ALTO CA 94301

(City) (State) (Zip)

1. Name and Address of Reporting Person \*

[Vivo Capital Fund VIII, L.P.](#)

(Last) (First) (Middle)  
C/O VIVO CAPITAL LLC  
192 LYTTON AVENUE

(Street)  
PALO ALTO, CA 94301

(City) (State) (Zip)

1. Name and Address of Reporting Person \*

[Vivo Capital Surplus Fund VIII, L.P.](#)

(Last) (First) (Middle)  
C/O VIVO CAPITAL LLC  
192 LYTTON AVENUE

(Street)  
PALO ALTO, CA 94301

(City) (State) (Zip)

1. Name and Address of Reporting Person \*

[Vivo Opportunity, LLC](#)

(Last) (First) (Middle)  
C/O VIVO CAPITAL LLC  
192 LYTTON AVENUE

(Street)  
PALO ALTO, CA 94301

(City) (State) (Zip)

1. Name and Address of Reporting Person \*

[Vivo Opportunity Fund, L.P.](#)

(Last) (First) (Middle)  
C/O VIVO CAPITAL LLC  
192 LYTTON AVENUE

(Street)  
PALO ALTO, CA 94301

(City) (State) (Zip)

**Explanation of Responses:**

1. These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").

2. These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").
3. These securities are held of record by Vivo Opportunity Fund, L.P. ("VOF").
4. Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
5. Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
6. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$21.9 to \$22.2, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
7. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$21.4 to \$21.6, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4

<a href="#"><u>/s/ Albert Cha as managing member of Vivo Capital VIII, LLC</u></a>	<a href="#"><u>02/11/2020</u></a>
<a href="#"><u>/s/ Albert Cha as a managing member of Vivo Capital VIII, LLC, the general partner of Vivo Capital Fund VIII, L.P.</u></a>	<a href="#"><u>02/11/2020</u></a>
<a href="#"><u>/s/ Albert Cha as a managing member of Vivo Capital VIII, LLC, the general partner of Vivo Capital Surplus Fund VIII, L.P.</u></a>	<a href="#"><u>02/11/2020</u></a>
<a href="#"><u>/s/ Albert Cha as a managing member of Vivo Opportunity, LLC.</u></a>	<a href="#"><u>02/11/2020</u></a>
<a href="#"><u>/s/ Albert Cha as a managing member of Vivo Opportunity, LLC, the general partner of Vivo Opportunity Fund, L.P.</u></a>	<a href="#"><u>02/11/2020</u></a>

\*\* Signature of Reporting Person    Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**